De-escalation from natalizumab in multiple sclerosis: Recurrence of disease activity despite switching to glatiramer acetate

Journal of Neurology

Volumn 258, Issue 9, 2011, Pages 1665-1669

  Havla, Joachim ^a   Gerdes, Lisa Ann ^a   Meinl, Ingrid ^a   Krumbholz, Markus ^a,b   Faber, Hans ^b   Weber, Frank ^b   Pellkofer, Hannah Luise ^a   Hohlfeld, Reinhard ^a   Kümpfel, Tania ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

De escalation; Glatiramer acetate; Multiple sclerosis; Natalizumab

Indexed keywords

GADOLINIUM; GLATIRAMER; NATALIZUMAB;

ADULT; ANNUAL RELAPSE RATE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RESPONSE TIME; TREATMENT DURATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTEGRINS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 80054720124     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-5996-y     Document Type: Article

References (12)

1. CH Polman PW O'Connor E Havrdova M Hutchinson L Kappos DH Miller JT Phillips FD Lublin G Giovannoni A Wajgt M Toal F Lynn MA Panzara AW Sandrock 2006 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 9 899 910 16510744 10.1056/NEJMoa044397 1:CAS:528:DC%2BD28XitVertL4%3D
2. RA Rudick WH Stuart PA Calabresi C Confavreux SL Galetta EW Radue FD Lublin B Weinstock-Guttman DR Wynn F Lynn MA Panzara AW Sandrock 2006 Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 9 911 923 16510745 10.1056/NEJMoa044396 1:CAS:528:DC%2BD28XitVertLw%3D
3. A Langer-Gould SW Atlas AJ Green AW Bollen D Pelletier 2005 Progressive multifocal leukoencephalopathy in a patient treated with natalizumab N Engl J Med 353 4 375 381 15947078 10.1056/NEJMoa051847 1:CAS:528:DC%2BD2MXms1Kntrc%3D (Pubitemid 41132342)
4. H Linda A von Heijne EO Major C Ryschkewitsch J Berg T Olsson C Martin 2009 Progressive multifocal leukoencephalopathy after natalizumab monotherapy N Engl J Med 361 11 1081 1087 19741229 10.1056/NEJMoa0810316 1:CAS:528: DC%2BD1MXhtFart77J
5. O Stuve CM Marra KR Jerome L Cook PD Cravens S Cepok EM Frohman JT Phillips G Arendt B Hemmer NL Monson MK Racke 2006 Immune surveillance in multiple sclerosis patients treated with natalizumab Ann Neurol 59 5 743 747 16634029 10.1002/ana.20858 1:CAS:528:DC%2BD28XkvFKhsLk%3D (Pubitemid 43673151)
6. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70 (13 Pt 2):1150-1151 (Pubitemid 351464749)
7. J Killestein A Vennegoor EM Strijbis A Seewann BW van Oosten BM Uitdehaag CH Polman 2010 Natalizumab drug holiday in multiple sclerosis: poorly tolerated Ann Neurol 68 3 392 395 20661928 10.1002/ana.22074
8. T Lenhard A Biller W Mueller I Metz J Schonberger B Wildemann 2010 Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 75 9 831 833 20805529 10.1212/WNL.0b013e3181f07362 1:STN:280: DC%2BC3cjosFOqtA%3D%3D
9. A Miravalle R Jensen RP Kinkel 2011 Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy Arch Neurol 68 2 186 191 20937940 10.1001/archneurol.2010.257
10. AD Goodman H Rossman A Bar-Or A Miller DH Miller K Schmierer F Lublin O Khan NM Bormann M Yang MA Panzara AW Sandrock 2009 GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study Neurology 72 9 806 812 19255407 10.1212/01.wnl.0000343880.13764.69 1:CAS:528:DC%2BD1MXit1Cgurw%3D
11. O Stuve PD Cravens EM Frohman JT Phillips GM Remington G von Geldern S Cepok MP Singh JW Cohen Tervaert M De Baets D MacManus DH Miller EW Radu EM Cameron NL Monson S Zhang R Kim B Hemmer MK Racke 2009 Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy Neurology 72 5 396 401 18987352 10.1212/01.wnl.0000327341.89587.76 1:STN:280: DC%2BD1M7ht1Orug%3D%3D
12. + T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis Arch Neurol 63 10 1383 1387 17030653 10.1001/archneur.63.10.1383 (Pubitemid 44547548)